surmount-1 tirzepatide non-diabetic obesity weight loss 💊 Could a new medication help reduce complications of obesity? The SURMOUNT-MMO trial investigates tirzepatide, a dual GIP and GLP-1 receptor agonist, in adults with or overweight but without diabetes. Researchers Read now: The SURPASS-EARLY trial

Altogether, these important findings may pave the way to developing novel antiviral strategies for treating infectious liver disease

~0.7mg 1.3mg 2.7mg 3x/week 3 injections/week P/T Ratio: ~1.6 Peak Reduction: 35% 4

However, individual timelines vary based on starting dose and personal physiology

Buffer systems in peptide formulations help resist pH changes that occur during storage

Hence, it is essential to take your healthcare provider onboard before including any new supplement into your diet or making any kind of lifestyle alterations, especially when you are dealing with certain health conditions or are pregnant